An­gling for a spot among the gi­ants, TG Ther­a­peu­tics touts PhI­II MS da­ta for CD20 drug

While the phar­ma gi­ants duke it out in mul­ti­ple scle­ro­sis, a biotech is tak­ing a crack at the shak­ing up the mar­ket.

TG Ther­a­peu­tics says they’ll be head­ed to the FDA in mid-2021 armed with strong late-stage da­ta on ubli­tux­imab, which led to re­duc­tions of around 60% and 50% in an­nu­al­ized re­lapse rate com­pared to Sanofi’s Auba­gio in a pair of Phase III tri­als (p<0.005). In each of the stud­ies, the ARR is less than 0.10.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER